PAWC
P.A.W. Capital Portfolio holdings
AUM
$51.9M
This Quarter Return
+24.69%
1 Year Return
+46.14%
3 Year Return
+74.13%
5 Year Return
+167.35%
10 Year Return
+839.74%
AUM
$88.8M
AUM Growth
+$88.8M
(+11%)
Cap. Flow
-$8.09M
Cap. Flow
% of AUM
-9.11%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
67
New
4
Increased
9
Reduced
20
Closed
4
Top Buys
| 1 |
Amplify Alternative Harvest ETF
MJ
|
$1.82M |
| 2 |
Regenxbio
RGNX
|
$1.72M |
| 3 |
Cantaloupe
CTLP
|
$581K |
| 4 |
RCM
R1 RCM Inc. Common Stock
RCM
|
$290K |
| 5 |
Exicure
XCUR
|
$235K |
Top Sells
| 1 |
EFII
Electronics for Imaging
EFII
|
$1.86M |
| 2 |
Chegg
CHGG
|
$1.52M |
| 3 |
CARB
Carbonite Inc
CARB
|
$1.26M |
| 4 |
VRTU
Virtusa Corporation
VRTU
|
$1.07M |
| 5 |
Marchex
MCHX
|
$945K |
Sector Composition
| 1 | Technology | 32.82% |
| 2 | Healthcare | 21.25% |
| 3 | Communication Services | 15.21% |
| 4 | Consumer Staples | 9.72% |
| 5 | Industrials | 6.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PVLA
26
Palvella Therapeutics, Inc. Common Stock
PVLA
$583M
| $838K | 0.83% |
250,000
-50,000
| -17% | -$168K |
|
27
AT&T
T
$208B
| $784K | 0.78% |
25,000
| – | – |
|
|
RDS.A
28
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $751K | 0.74% |
12,000
| – | – |
|
29
Merck
MRK
$214B
| $749K | 0.74% |
9,000
| – | – |
|
30
Galmed Pharmaceuticals
GLMD
$6.96M
| $735K | 0.73% |
90,000
| – | – |
|
31
Abbott
ABT
$229B
| $719K | 0.71% |
9,000
| – | – |
|
32
Verizon
VZ
$185B
| $710K | 0.7% |
12,000
| – | – |
|
33
Philip Morris
PM
$261B
| $707K | 0.7% |
8,000
| – | – |
|
|
34
Exicure
XCUR
$34.6M
| $705K | 0.7% |
300,000
+100,000
| +50% | +$235K |
|
35
BP
BP
$90.8B
| $700K | 0.69% |
16,000
| – | – |
|
36
Johnson & Johnson
JNJ
$429B
| $699K | 0.69% |
5,000
| – | – |
|
37
Altria Group
MO
$113B
| $689K | 0.68% |
12,000
| – | – |
|
38
Ares Capital
ARCC
$15.7B
| $686K | 0.68% |
40,000
| – | – |
|
39
Chevron
CVX
$326B
| $677K | 0.67% |
5,500
| – | – |
|
40
Procter & Gamble
PG
$370B
| $676K | 0.67% |
6,500
-500
| -7% | -$52K |
|
41
PepsiCo
PEP
$206B
| $674K | 0.67% |
5,500
-500
| -8% | -$61.3K |
|
42
GSK
GSK
$78.5B
| $669K | 0.66% |
16,000
| – | – |
|
43
Weyerhaeuser
WY
$18B
| $659K | 0.65% |
25,000
+5,000
| +25% | +$132K |
|
44
Exxon Mobil
XOM
$489B
| $646K | 0.64% |
8,000
| – | – |
|
45
DuPont de Nemours
DD
$31.7B
| $640K | 0.63% |
12,000
| – | – |
|
46
BlackRock TCP Capital
TCPC
$606M
| $638K | 0.63% |
45,000
| – | – |
|
47
Pfizer
PFE
$142B
| $637K | 0.63% |
15,000
| – | – |
|
48
Morgan Stanley
MS
$238B
| $633K | 0.63% |
15,000
+5,000
| +50% | +$211K |
|
49
Coca-Cola
KO
$297B
| $609K | 0.6% |
13,000
| – | – |
|
50
JPMorgan Chase
JPM
$824B
| $607K | 0.6% |
6,000
| – | – |
|